Literature DB >> 15569855

Selective silencing of angiotensin receptor subtype 1a (AT1aR) by RNA interference.

Jorge Vázquez1, María F Correa de Adjounian, Colin Sumners, Aaron González, Carlos Diez-Freire, Mohan K Raizada.   

Abstract

Angiotensin II exerts its physiological effects by activating multiple subtypes of its receptor such as AT1a-, AT1b-, and AT2-receptors. Because of a high degree of similarity among these G-protein-coupled receptors, it has been difficult to assign diverse physiological actions of angiotensin II through these receptor subtypes. We have developed small interfering RNAs to selectively inhibit the expression of the AT1a receptor (AT1aR) subtype. A dsRNA, AT1 47, was found to be highly selective and efficient in reducing the levels of AT1aR subtype. Transfection of AT1aR-expressing CHO cells with dsRNA AT1 47 resulted in an 80% decrease in the AT1aR expression. In contrast, dsRNA AT1 47 showed no significant effects on both AT1bR and AT2R subtypes. Thus, AT1 47 provides us with a powerful tool to selectively silence this subtype of receptor to investigate its role in cardiovascular physiology.

Mesh:

Substances:

Year:  2004        PMID: 15569855     DOI: 10.1161/01.HYP.0000150161.78556.c6

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Selective knockdown of AT1 receptors by RNA interference inhibits Val5-ANG II endocytosis and NHE-3 expression in immortalized rabbit proximal tubule cells.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Am J Physiol Cell Physiol       Date:  2007-04-11       Impact factor: 4.249

2.  Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct.

Authors:  Bing S Huang; Aidong Chen; Monir Ahmad; Hong-Wei Wang; Frans H H Leenen
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

3.  Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.

Authors:  Baojian Xue; Terry G Beltz; Yang Yu; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-26       Impact factor: 4.733

4.  AT1 receptor-mediated accumulation of extracellular angiotensin II in proximal tubule cells: role of cytoskeleton microtubules and tyrosine phosphatases.

Authors:  Xiao C Li; Oscar A Carretero; L Gabriel Navar; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2006-02-14

5.  Knockdown of mineralocorticoid or angiotensin II type 1 receptor gene expression in the paraventricular nucleus prevents angiotensin II hypertension in rats.

Authors:  Aidong Chen; Bing S Huang; Hong-Wei Wang; Monir Ahmad; Frans H H Leenen
Journal:  J Physiol       Date:  2014-06-27       Impact factor: 5.182

6.  AT1 receptor-mediated uptake of angiotensin II and NHE-3 expression in proximal tubule cells through a microtubule-dependent endocytic pathway.

Authors:  Xiao C Li; Ulrich Hopfer; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-02

7.  Effects of AT1 receptor-mediated endocytosis of extracellular Ang II on activation of nuclear factor-kappa B in proximal tubule cells.

Authors:  Jia L Zhuo; Oscar A Carretero; Xiao C Li
Journal:  Ann N Y Acad Sci       Date:  2006-12       Impact factor: 5.691

8.  New aspects of gene-silencing for the treatment of cardiovascular diseases.

Authors:  Olivia Koenig; Tobias Walker; Nadja Perle; Almuth Zech; Bernd Neumann; Christian Schlensak; Hans-Peter Wendel; Andrea Nolte
Journal:  Pharmaceuticals (Basel)       Date:  2013-07-19

9.  Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension.

Authors:  Jia Liu; Jiamei Liu; Linying Shi; Fan Zhang; Liping Yu; Xinchun Yang; Jun Cai
Journal:  Int J Mol Med       Date:  2018-01-23       Impact factor: 4.101

Review 10.  Therapeutic opportunities of small interfering RNA.

Authors:  Bhoomika R Goyal; Mayur M Patel; Mithil K Soni; Shraddha V Bhadada
Journal:  Fundam Clin Pharmacol       Date:  2009-08       Impact factor: 2.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.